Anti-Mouse CD120b (TNFR2) [Clone TR75-54.7] — Purified in vivo PLATINUM™ Functional Grade

Clone TR75-54.7 is most commonly used in vivo in mice to block or study signaling through TNFR2 (CD120b), facilitating research in immunoregulation, tumor immunology, and therapeutic interventions targeting TNF receptor pathways.

Key in vivo applications include:

• Anti-tumor studies: TR75-54.7 is widely used to investigate the role of TNFR2 in tumor growth and anti-tumor immunity. When administered to tumor-bearing mice (e.g., 4T1 breast cancer model), TR75-54.7 suppresses tumor progression, augments anti-tumor immune responses, and can increase overall survival. It is often evaluated alone or in combination with other antibodies (e.g., anti-PD-L1 or anti-CD25) to enhance immunotherapeutic effects.
• Immunoregulation: Since TNFR2 is expressed on various immune cells (including regulatory T cells, or Tregs), TR75-54.7 is used to modulate or dissect their function in vivo, particularly by blocking TNFα/TNFR2 interactions that influence Treg expansion, suppression, or activation. Studies have directly compared TR75-54.7 with antibodies against other immune checkpoints, highlighting its unique effects on Treg biology and tumor rejection.
• Functional blockade of TNFR2: TR75-54.7 is a well-characterized blocking antibody, used to inhibit ligand-induced receptor signaling in vivo, enabling exploration of TNFR2-dependent pathways such as apoptosis, NF-κB activation, inflammation, and hematopoiesis. This blockade is leveraged in disease models to study the consequences of TNFR2 inhibition on immune responses and disease progression.
• Preclinical therapeutic testing: Due to its blocking properties and validated in vivo activity, TR75-54.7 is used in preclinical models testing the potential of TNFR2-targeted therapies—often as a comparator or adjunct in evaluating novel cancer immunotherapies.

TR75-54.7 is used in other technical applications (like flow cytometry, immunoprecipitation, and ELISA), but in vivo, its roles are predominantly focused on anti-tumor efficacy, immune modulation, and pathway blockade in mouse models.

TR75-54.7, an anti-mouse TNFR2 antibody, is commonly paired with several other antibodies and proteins in research applications. The most frequently used companion reagents include:

TR75-32.4 is the primary antibody used alongside TR75-54.7, particularly for ELISA applications. TR75-54.7 serves as the capture antibody while biotinylated TR75-32.4 functions as the detecting antibody. This pairing creates an effective sandwich ELISA system for detecting mouse TNFR2.

PC61, an anti-CD25 antibody, is frequently combined with TR75-54.7 for in vivo functional studies. This combination has proven particularly effective in cancer immunotherapy research. In mouse 4T1 breast cancer models, the combination of TR75-54.7 and PC61 demonstrated superior antitumor effects compared to either antibody alone, with the combination therapy extending median survival to 38 days compared to 34 days for TR75-54.7 alone or 27 days for PC61 alone.

TR75-89 represents another anti-TNFR2 monoclonal antibody that has been investigated alongside TR75-54.7. While both antibodies act as TNFR2 agonists, they differ in their mechanism—TR75-54.7 competes with TNF-α for binding, whereas TR75-89 does not compete with TNF-α.

For secondary detection in flow cytometry applications, biotinylated anti-Armenian hamster IgG antibodies are recommended, often followed by streptavidin-conjugated fluorochromes to amplify signal detection. This three-layer staining technique helps maximize signal over background in immunofluorescent staining applications.

Clone TR75-54.7 is a monoclonal antibody that targets mouse Tumor Necrosis Factor Receptor Type II (TNFR2), also known as CD120b or p75. Here are the key findings from its citations in scientific literature:

1. TNFR2 Agonist and Antagonist Activities:

   • TNFR2 Agonist: When cross-linked in vitro, TR75-54.7 acts as a TNFR2 agonist, promoting cell proliferation and NF-κB activation, which are crucial for various biological processes including immunoregulation and cell differentiation.
   • TNFR2 Antagonist: TR75-54.7 also exhibits blocking activity, which is useful for preventing ligand-induced receptor signaling.

2. Enhanced Anti-Tumor Immunity:

   • In mouse models, TR75-54.7 has been shown to enhance anti-tumor immunity. It acts by modulating the immune environment, potentially by affecting T regulatory cells (Tregs) that express TNFR2.
   • The combination of TR75-54.7 with other immunotherapies, such as CD25 antagonistic antibodies, leads to enhanced antitumor effects compared to monotherapies.

3. Comparison with Other Therapies:

   • TR75-54.7 has been compared with CD25-targeting antibodies like PC61. Studies indicate that TR75-54.7 is superior in inhibiting tumor growth and enhancing survival in animal models.
   • Combining TR75-54.7 with anti-PD-L1 antibodies has also shown augmented antitumor effects compared to monotherapy.

4. Basic Characteristics:

   • TR75-54.7 is a hamster-derived monoclonal antibody of the IgG isotype, making it suitable for various research applications, including flow cytometry and ELISA.

Overall, clone TR75-54.7 is a valuable tool for studying TNFR2's role in immune regulation and cancer therapy, offering both agonist and antagonist activities depending on the context.

Dosing regimens for clone TR75-54.7, an anti-mouse TNFR2 antibody, vary across different mouse models primarily based on three key factors: mouse strain, tumor type, and experimental design. Here are some specific considerations:

• Mouse Strain: Protocols can differ significantly depending on the mouse strain used, such as FVB/n, C57BL/6j, and NSG mice, often used in various cancer models like pancreatic cancer.

• Tumor Type: The tumor type can influence dosing. For example, in breast cancer models like the 4T1 model, the TR75-54.7 antibody may be administered intraperitoneally before tumor inoculation to study its antitumor effects.

• Experimental Design: The design of the experiment, including the timing and frequency of antibody administration, can be tailored to the specific research question. For instance, in some studies, the antibody is given before tumor inoculation to assess its impact on tumor development. In other cases, it may be given after tumor implantation to study its effects on established tumors.

These variations allow researchers to optimize treatment strategies for different research models, ensuring the most effective outcomes in preclinical studies. Specific dosages and administration schedules can be found in the detailed protocols for each model. For example, in some studies, mice are treated with 100 μg of anti-TNFR2 mAb intraperitoneally at specific intervals after tumor implantation. However, the exact dosing regimen should be determined based on the specific requirements of the model being used.